Trials
2 active
6 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “AL102 is an inhibitor of gamma secretase-mediated Notch signaling.”In the company’s words, NCT04871282 on ClinicalTrials.gov
- Tested for
- Desmoid, Desmoid Tumor
- Main trialPhase 2/3
- “The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.”In the company’s words, NCT04871282 on ClinicalTrials.gov
- Other names
- AL102
Other drugs for Desmoid Tumor
- FOG-001Parabilis Medicines, Inc. · Phase 1/2
- ES014Elpiscience (Suzhou) Biopharma, Ltd. · Phase 2
- E7386Eisai · Phase 1
- ST316Sapience Therapeutics · Phase 1
- NirogacestatSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · Marketed (Phase 4 trial)
Coming up1
- May 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Active, not recruiting | 3 Dec 2025 | A Study of AL102 in Patients With Progressing Desmoid Tumors | |
| Phase 1Recruiting | May 2027 | A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants | |
| Phase 1Completed | 30 Dec 2024 | A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants | |
| Phase 1Completed | 11 Mar 2025 | A Phase 1 Mass Balance Study of Varegacestat | |
| Phase 1Completed | 8 Apr 2025 | A Cardiac Liability Study of Varegacestat in Healthy Participants | |
| Phase 1Completed | 5 Nov 2025 | A Varegacestat Hepatic Impairment Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026